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Abstract
Background: Postoperative interferon-α(IFN-α) treatment delays hepatocellular carcinoma(HCC) recurrence and
prolongs patient survival, and may thus be an effective form of adjuvant therapy. However, clinical observations
found that HCC recurs in some patients within 8 months of IFN-α treatment being discontinued. We investigated
whether HCC regrowth appears after IFN-α is discontinued, whether re-initiated IFN-α is effective, and the
underlying mechanisms of IFN-α treatment.
Methods: The human HCC nude mouse model LCI-D20 was used to study the effects of IFN-α treatment,
discontinued IFN-α treatment, and re-initiated IFN-α treatment on tumor growth. Tumor weight, microvessel
density(MVD), serum vascular endothelial growth factor (VEGF), and tumor cell apoptosis were analyzed.
Angiogenesis-related factors were studied using cDNA microarray in different tumor samples and confirmed using
reverse transcription–polymerase chain reaction(RT-PCR) and Western blotting assays. Finally, imatinib was added
with re-initiated IFN-α treatment to improve efficacy.
Results: IFN-α (1.5×107 U/kg/day for 20 days) suppressed HCC growth by 60.3% and decreased MVD by 52.2%
compared with the control. However, tumor regrowth occurred after IFN-α was discontinued, and re-initiated IFN-α
treatment was not effective for inhibiting tumor growth or reducing MVD compared with a saline-treated group.
cDNA microarray showed VEGF was down-regulated while platelet-derived growth factor-A (PDGF-A) was
up-regulated when IFN-α treatment was re-initiated. These findings were further confirmed with RT-PCR and
Western blotting assay. The combination of imatinib with re-initiated IFN-α reduced HCC weight by 30.7% and
decreased MVD by 31.1% compared with IFN-α treatment only (P=0.003 and 0.015, respectively).
Conclusion: Tumor regrowth occurred after IFN-α treatment was discontinued. Re-initiated IFN-α treatment was
not effective and was associated with up-regulation of PDGF-A, while the VEGF remained suppressed. The
combination of a PDGF-receptor inhibitor with IFN-α improved the effect of the re-initiated treatment.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in men and the seventh most common can-
cer in women, with an estimated 749,000 new cases and
695,000 deaths worldwide in 2008 [1]. HCC is usually a
hypervascular tumor [2], and therefore a good target for
anti-angiogenic gene therapy [3]. Although several sig-
naling pathways are involved in angiogenesis, attention
has been focused on the vascular endothelial growth fac-
tor (VEGF) family [4], especially VEGF-A, which binds
and activates VEGF receptor-2 [5-7] and thereby stimu-
lates endothelial migration and proliferation [7-10].
Interferon α (IFN-α) inhibits tumor cell production of
VEGF [11,12] and endothelial cell motility and has both
direct and indirect anti-angiogenesis activity [13]. As a
recombinant protein, IFN-α is one of a few approved
angiogenesis inhibitors, and it has been applied in the
clinical treatment of HCC [14-16], renal cancer [17],
prostate cancer [18], malignant melanoma [19-22],
chronic myelogenous leukemia [23-25], and superficial
bladder carcinoma [26].
Our previous randomized control trial showed that 18
months of postoperative IFN-α treatment delayed recur-
rence and prolonged patient survival [16], which is gener-
ally consistent with the findings of other studies [27,28].
We also found that P48 expression can be a selection bio-
marker for receiving IFN-α treatment [29]. However, we
also found that tumors recurred shortly after IFN-α treat-
ment was discontinued in some patients.
Based on this finding, the current study investigated
whether tumor relapse is inevitable after IFN-α treatment
is stopped and whether re-initiated IFN-α treatment is ef-
fective. The results demonstrated that regrowth of tumor
vessels is certain after IFN-α therapy is discontinued; fur-
ther, tumor growth is not inhibited when IFN-α treatment
is re-initiated and re-initiated treatment is associated with
increased platelet-derived growth factor (PDGF)-A expres-
sion. Pericytes are another vascular cell type that provide
endothelial cells with crucial survival signals [30,31], and
the PDGF/PDGF-receptor (PDGFR) pathway has been
shown to regulate pericyte homeostasis. Therefore, we
hypothesized that up-regulation of PDGF-A is responsible
for the failure of re-initiated IFN-α treatment against
HCC. To test this hypothesis, we added imatinib [32,33]
(Gleevec, Novartis, Basel, Switzerland), a PDGFR inhibitor,
to the re-initiated IFN-α treatment, which resulted in sig-
nificant inhibition of tumor growth and angiogenesis. In
summary, the results indicated that up-regulation of
PDGF-A is responsible for the failure of re-initiated IFN-α
treatment when tumors recur after initial IFN-α therapy is
discontinued, and long-term disease control may be
achieved by combination therapy with imatinib in a re-
initiated IFN-α treatment course.
Methods
Animals
Male BALB/c nu/nu mice (4–6 weeks old) weighing ap-
proximately 20 g (Shanghai Institute of Materia Medica,
Chinese Academy of Sciences, Shanghai) were housed in
laminar-flow cabinets under specific pathogen-free
conditions. The experimental protocol was approved
by the Shanghai Medical Experimental Animal Care
Figure 1 Experimental design and grouping. Groups A and B show whether IFN-α inhibits tumor growth; groups C and D, whether tumors
regrow after IFN-α is discontinued; groups E and F, whether re-initiated IFN-α treatment remains effective; groups G and H, whether the efficacy
of IFN-α was influenced by tumor size at the beginning of the treatment.
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Committee. The model of human HCC in nude mice
(LCI-D20) established in our institute [12,34] via ortho-
topic implantation of a histologically intact metastatic
tumor tissue (at an average volume of 1 mm3) was used
in this study.
Design of animal study
To observe the effect of IFN-α treatment, 12 HCC-
bearing mice were randomized to receive normal saline
(group A, subcutaneous injection of 0.2 ml normal sa-
line, n=6) or IFN-α (group B, subcutaneous injection of
0.2 ml at a dose of 1.5×107 U/kg/day, n=6; recombinant
human interferon-α-1b, Kexing Bioproducts Co., Shen-
zhen, China) [34]. Treatment was started on day 7 after
implantation and continued for 20 days (Figure 1, Add-
itional file 1: Figure S1).
To examine tumor growth after discontinuation of
IFN-α treatment, 12 HCC-bearing mice were first trea-
ted with normal saline (group C) or IFN-α (group D) for
20 days, after which treatment was discontinued and the
mice observed for another 20 days (both groups, n=6).
To further investigate the effect of re-initiated IFN-α
treatment, another 12 HCC-bearing mice were first trea-
ted with IFN-α for 20 days at the same dosage as group
B, then observed for another 20 days after treatment was
discontinued. The mice were then randomized to receive
either normal saline (group E, n=6) or IFN-α (group F,
n=6, at the group B dosage) for 20 days.
To study the effect of IFN-α treatment on a relatively
larger tumor, tumors were allowed to grow for 35 days
after implantation in 12 HCC-bearing mice (tumor
weight was approximately 1.5 g, the same size as the
tumor at the beginning of the re-initiated IFN-α treat-
ment). Mice were then randomized to receive either nor-
mal saline (group G, n=6) or IFN-α at a dose of 1.5 ×
107 U/kg/day (group H, n=6) for 20 days.
Enzyme-linked immunosorbent assay
The serum VEGF concentration was analyzed by
enzyme-linked immunosorbent assay (ELISA) using the
Quantikine VEGF ELISA kit (R&D Systems, Minneap-
olis, MN). All analyses were conducted in duplicate. The
concentrations of VEGF in unknown samples were
determined by comparing the optical density of the sam-
ples to the standard curve.
Immunohistochemistry
The immunohistochemical study was performed as
detailed previously[35]. The primary antibody was rat
anti-mouse CD31 (1:40, BD Biosciences, San Jose, CA) to
measure MVD. The components of Envision-plus detec-
tion system (EnVision+/HRP/Mo; Dako, Carpinteria, CA)
were applied. Reaction products were visualized by incu-
bation with 3,3’-diaminobenzidine. Negative controls were
treated identically but with the primary antibody omitted.
To measure MVD, any brown-staining endothelial cell
cluster distinct from adjacent microvessels, tumor cells, or
other stromal cells was considered a single countable
microvessel. The entire section was observed under low
magnification, and three highly vascularized areas per
tumor were then evaluated at high magnification (200×).
Immunofluorescence double staining for CD31
(endothelial cells), α smooth muscle actin (α-SMA), and
TUNEL
Frozen tissues were sectioned into 8-μm-thick slices,
which were stained with rat anti-mouse CD31 (1:40, BD
Biosciences) overnight. Bound antibodies were detected
by incubation with biotin-coupled rabbit anti-rat anti-
body (1:200, Southern Biotech, Birmingham, AL), sec-
tions were then incubated for 30 min at room
temperature with DyLight 488 streptavidin (1:500, Vec-
tor, Burlingame, CA). Vascular pericyte staining with
anti-α-SMA (1:100, sigma, St. Louis, MO) was per-
formed. The biotin-conjugated secondary antibody and
DyLight 549 streptavidin (1:500, Vector, Burlingame,
CA) were used to visualize pericytes simultaneously.
Terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick-end labeling was used to detect apoptosis
according to the manufacturer’s instructions. The apop-
totic tumor cells within areas of a viable tumor were
counted (more than 2000 cells in each sample) at 400×
magnification and proliferative indexes were calculated.
cDNA microarray analysis
The GEArray Q Series Angiogenesis Gene Array kit
(SuperArray Bioscience, Bethesda, MD) was used to
characterize the gene expression profiles of differently
treated mice. Hybridization was performed according to
the manufacturer’s instructions, as described previously
[34,36]. Experiments were performed in duplicate, and
the reproduction rate was >98% between experiments.
RNA extraction and reverse transcription–polymerase
chain reaction (RT-PCR)
Total RNA was extracted by the Trizol method (Life
Technologies Inc., Grand Island, NY). RNA was pre-
treated with DNase I (Invitrogen, Carlsbad, CA), and 3
μg of RNA was subjected to reverse transcription at 42°
C for at least 1 h in a 20-μl reaction mixture. The PCR
products were analyzed by electrophoresis in a 1.5%
agarose gel. Details on the VEGF [37] and GAPDH pri-
mers and the reaction parameters are provided in Add-
itional file 1: Table S1.
Real-time quantitative PCR
The ABI Prism Primer Express Software (Applied Bio-
systems, Foster City, CA) was used to design probes,
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forward primers, and reverse primers of VEGF165 [38],
PDGF-A, and GAPDH (Additional file 1: Table S2, San-
gon Biotech, Shanghai, China). An ABI Prism 7700 Se-
quence Detection System (Applied Biosystems) was used
to analyze RT-PCR, as described previously [38]. The
relative amounts of VEGF165 and PDGF-A mRNA were
calculated as detailed previously [39].
Protein extraction and western blotting assay
Protein expression was assessed only in the non-necrotic
part of the tumor. Western blotting was performed for
rabbit anti-VEGF, rabbit anti-PDGF-A (Santa Cruz),
rabbit anti-phosphor-VEGF receptor-2 tyrosine 951, rabbit
anti-phosphor-PDGF receptor α tyrosine 754, rabbit anti-
AKT, rabbit anti-phosphor-AKT, rabbit anti-ERK, rab-
bit anti-phosphor-ERK, and mouse anti-β-actin (Cell
Signaling Technology, Beverly, MA) after SDS-PAGE
and electrophoretic transfer to polyvinylidene fluoride
membranes. Then incubation was performed with horse-
radish peroxidase–conjugated goat anti-rabbit or goat
anti-mouse antibodies (Amersham Life Technologies,
Arlington Heights, IL) for 1 h.
Statistical analysis
Continuous data were expressed as mean and standard
deviation or mean and 95% confidence intervals (CIs).
Groups were compared with the Mann–Whitney U-test
using the software package SPSS 10.0 (SPSS Inc.,
Chicago, IL). All tests were two-tailed, and data were
considered to be statistically significant at P < 0.05.
Results
IFN-α inhibited tumor growth but tumor regrowth
occurred rapidly after it was discontinued
Tumors in IFN-α treatment group B were smaller than
those in control group A (0.27 ± 0.19 g vs. 0.68 ± 0.24 g,
P = 0.009; Figure 2A). The serum VEGF levels were also
lower in the IFN-α–treated mice than in the control
mice (24.5 ± 8.7 pg vs. 41.6 ± 12.0 pg/ml, P = 0.018,
Figure 2B), and MVD was also markedly decreased
(Figure 2C), with a mean MVD of 22/HP (95% CI = 15–
29/HP) in group B versus 46/HP (95% CI = 32–60/HP,
P = 0.004) in group A. Furthermore, a higher apoptotic
rate (Figure 2D) was found in IFN-α–treated tumors
compared with control tumors (8.60% ± 2.42% vs. 3.47%
± 1.13%, P = 0.001).
However, there was no significant difference in the
tumor weight and MVD between groups C and D when
IFN-α treatment was discontinued for 20 days (1.93 ±
0.58 g vs. 1.54 ± 0.49 g, P = 0.233; 59, 95% CI = 43–73
vs. 51, 95% CI = 38–64, P = 0.369, respectively). Serum
VEGF levels in group D were not statistically different
from those in control group C (54.3 ± 13.8 pg/ml vs.
63.7 ± 17.5 pg/ml, P = 0.327) and were much higher
than those in group B immediately after the first treat-
ment course (Figure 2), suggesting a significant relapse
of tumor growth and angiogenesis happened after IFN-α
treatment was stopped.
Re-initiated IFN-α treatment did not suppress tumor
growth
No significant inhibitory effect on tumor size (3.81 ±
0.92 g vs. 3.22 ± 0.62 g, P = 0.217), MVD (70, 95% CI =
59–81 vs. 61, 95% CI = 48–74, P = 0.198) and apoptotic
index (4.84% ± 1.16% vs. 5.56% ± 1.41%, P = 0.360)
(Figure 2) was observed between group E (normal saline
control) and group F (re-initiated IFN-α treatment).
However, the serum VEGF concentration in group F was
decreased again when IFN-α treatment was re-initiated
as compared with control mice (92.8 ± 24.3 pg/ml vs.
58.0 ± 13.7 pg/ml, P = 0.012, Figure 2B).
Tumor response to IFN-α treatment was not influenced
by pre-treatment tumor size
It is possible that poorer tumor response to re-initiated
IFN-α treatment may result from a larger tumor size
prior to treatment. To test this hypothesis, tumors were
allowed to grow for 35 days until the tumor weight was
about 1.5 g (the same size as the tumor at the beginning
of the re-initiated IFN-α treatment). IFN-α treatment for
20 days (group H) resulted in a significant reduction of
tumor weight compared with control group G (2.28 ±
0.63 vs. 3.90 ± 0.80 g, P = 0.003), which suggested that
the reduced inhibitory effect of re-initiated IFN treat-
ment was not influenced by the pre-treatment tumor
size.
Effect of IFN-α treatment on apoptosis of endothelial cells
Double immunofluorescence staining of apoptotic cells
and endothelial cells was used to investigate whether
IFN-α treatment resulted in endothelial cell apoptosis.
IFN-α treatment induced a marked increase of endothe-
lial cell apoptosis and decreased MVD in group B
compared with control group A. In the mice treated by
re-initiated IFN-α, very few apoptotic endothelial cells
could be detected in groups E and F, both of which had
a higher MVD (Figure 3A).
Changes in the angiogenesis-related gene expression
profile of HCC induced by IFN-α treatment
Two independent cDNA microarray analyses showed that
IFN-α treatment down-regulated several pro-angiogenesis
factors, including VEGF, angiogenin, basic fibroblast growth
factor (bFGF), PDGF-A, transforming growth factor (TGF),
tumor necrosis factor (TNF), granulocyte colony stimulat-
ing factor (G-CSF), epidermal growth factor (EGF), insulin-
like growth factor (IGF), and interleukin (IL)-8 in the first
treatment course. All the pro-angiogenesis factors except
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PDGF-A were again down-regulated in group F when com-
pared with group E (Table 1).
Effects of IFN-α on the expression of VEGF165, PDGF-A,
and VEGF receptor(VEGFR)-2
PCR showed two transcripts whose base-pair length cor-
responded to those of VEGF165 and VEGF121, as well
as a small transcript corresponding to VEGF189
(Figure 3B). IFN-α treatment decreased VEGF165 ex-
pression in the first IFN-α treatment group (group B)
and the re-initiated IFN-α treatment group (group F)
compared with their control groups A and E, respect-
ively. PDGF-A expression was decreased in group B
compared with control group A, but increased in the
re-initiated IFN-α treatment group F compared with
control group E (Figure 3C, 3D). These results were
consistent with the cDNA microarray analyses.
Western blotting for VEGF165 of HCC tissues under re-
ducing conditions showed two bands of 23 and 21 kDa,
respectively (Figure 4A), consistent with two glycosylation
variants of VEGF165. No other isoform of VEGF was
detected. Tumors from group B expressed a lower level of
VEGF165 than those of group A. Similarly, the VEGF165
concentration of group F was lower than that of group E.
In addition, VEGF receptor-2 phosphorylation of Y951,
which plays a critical role in pathological angiogenesis,
was higher in control groups A and E but present at a very
low level in the IFN-α–treated groups B and F, which sug-
gests IFN-α retained its ability to inhibit VEGF signaling
in the first and re-initiated treatment courses. PDGF-A in
group B was down-regulated significantly compared with
control group A. However, in the second IFN-α treatment
course, group F had a higher PDGF-A level than its con-
trol group E (Figure 4).
Figure 2 Effects of IFN-α on (A) tumor weight, (B) serum VEGF level, (C) angiogenesis, and (D) apoptotic index. Representative photo-micrographs
of immunohistochemical and TUNEL analysis of MVD and apoptotic cells performed as described in Materials and methods, scale bar = 20 μm.
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Blockage of PDGF signaling by imatinib significantly
improved the efficacy of re-initiated IFN-α treatment
Combination treatment with imatinib and IFN-α
resulted in the decrease of PDGF receptor phosphoryl-
ation level and a lower AKT and ERK phosphorylation
level, compared with IFN treatment alone or the control
group (Figure 5A). Meanwhile, tumor growth was inhib-
ited significantly (2.23 ± 0.43 g) in the combination
treatment group in contrast with IFN-α treatment alone
(3.22 ± 0.62 g, P = 0.01), imatinib treatment alone (3.10
± 0.62 g), and the normal saline group (3.81 ± 0.92 g,
P = 0.003). The difference in tumor size between IFN-
Figure 3 PDGF-A expression was increased in IFN-α re-initiated treatment course. (A) Endothelial cell (red:CD31 staining/DyLight 488) and
apoptosis (green: TUNEL/FITC) were examined. The first IFN-α treatment resulted in marked endothelial cell apoptosis (yellow), but the re-initiated
IFN-α treatment did not (scale bar = 20 μm). (B) Expression of VEGF at the mRNA level in HCC. RT-PCR for GAPDH was used to compare input
mRNA integrity. (C) Effect of IFN-α on the expression of VEGF165 and PDGF-A, determined with RT-PCR and normalized to GAPDH expression. An
asterisk indicates statistical significance when compared with corresponding control groups (P < 0.05).
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α or imatinib treatment alone and the control group
was not significant(P = 0.751). Furthermore, the de-
crease in angiogenesis was demonstrated by lower
MVD in IFN-α combined with imatinib treatment
group (42, 95% CI = 32–52) compared with IFN-α
treatment alone (61, 95% CI = 48–74, P = 0.015). The
results of immunofluorescence double staining showed
that, compared with the groups treated with IFN-α or
normal saline, the tumor vessels in the combined
treatment group had fewer signals detected by anti-α-
SMA antibody (Figure 5).
Discussion
This study demonstrated in the human HCC xenograft LCI-
D20 mouse model that tumor regrowth is inevitable when
IFN-α treatment is discontinued. Re-initiated IFN-α treat-
ment was less effective than the first treatment course and
was associated with an elevated expression of PDGF-A.
Blockage of the PDGF/PDGFR pathway by imatinib signifi-
cantly improved the efficacy of re-initiated IFN-α treatment.
Anti-angiogenesis treatment is less likely to induce
acquired drug resistance because it targets genetically
stable endothelial cells rather than unstable mutating
tumor cells [40]. However, acquired resistance may
eventually develop when using some signal transduction
inhibitors that exclusively target a cancer cell–associated
genetic or phenotypic alteration [41-44]. One of the
underlying mechanisms could be activation of another
pro-angiogenesis pathway [42,43,45]. Inevitable tumor
regrowth after discontinuation of IFN-α treatment in the
present study was consistent with the findings from our
randomized clinical trials, in which 18-month postopera-
tive IFN-α treatment delayed but did not reduce tumor
recurrence during long-term follow-up [16].
We examined whether re-initiated IFN-α treatment is
effective for tumors that were initially treated with IFN-
α. Our findings showed that re-initiated IFN-α treatment
was less effective in suppressing tumor growth com-
pared with the first treatment course. Further, the lower
efficacy was not associated with pretreatment tumor
size, implying that outgrowth of a specific subpopula-
tion, under the selection of IFN-α treatment, may pro-
duce alternative pro-angiogenesis factors or activate an
alternative pathway. To test this hypothesis, we analyzed
the expression level of several angiogenesis-related genes
by cDNA microarray to screen the differentially
expressed factors during the first and re-initiated treat-
ment courses and verified the results by RT-PCR
and Western blotting assay. In the re-initiated treat-
ment course, the pro-angiogenesis factor PDGF-A was
up-regulated, which may be partially responsible for
activating angiogenesis and compromising the VEGF
down-regulating effects. PDGF-A released by the tumor
cells induces proliferation and migration of endothelial
cells and vascular smooth muscle cells, suggesting a dir-
ect role for PDGF-A in angiogenesis. In human gastric
cancers, high levels of PDGF-A correlate with high-
grade carcinomas and reduced patient survival time [46].
Heinrich and colleagues’ elegant study also identified
PDGFRα-activating mutations in a subset of human
gastrointestinal stromal tumors, for which PDGFRα may
prove to be a useful molecular marker and therapeutic
Table 1 The consecutive changes of some pro-angiogenic factors in the first and re-initiated IFN-α treatment course













Hs.283749 NM_001145 Angiogenin, RNase A family, 5 ribonuclease ANG 0.404 0.275 0.418 0.326
Hs.2233 NM_000759 Colony stimulating factor 3 (granulocyte) CSF3 0.179 0.117 0.400 0.032
Hs.419815 NM_001963 Epidermal growth factor (beta- urogastrone) EGF 0.270 0.204 0.057 0.045
Hs.284244 NM_001006 Fibroblast growth factor 2 (basic) FGF2 0.236 0.163 0.014 0.011
Hs.396530 NM_000601 Hepatocyte growth factor HGF 0.414 0.140 0.074 0.026
Hs.308053 NM_000618 Insulin-like growth factor 1 (somatomedin C) IGF1 0.242 0.062 0.032 0.006
Hs.624 NM_000583 Interleukin 8 IL-8 0.235 0.130 0.020 0.017
Hs.367877 NM_004530 Matrix metalloproteinase 2 MMP2 0.171 0.071 0.014 0.010
Hs.151738 NM_004994 Matrix metalloproteinase 9 MMP9 0.179 0.069 0.012 0.010
Hs.376032 NM_002607 Platelet-derived growth factor alpha polypeptide PDGFA 0.212 0.054 0.131 0.200
Hs.252820 NM_002632 Placental growth factor PGF 0.050 0.021 0.040 0.008
Hs.196384 NM_000963 Prostaglandin-endoperoxide synthase 2 PTGS2 0.137 0.063 0.069 0.041
Hs.170009 NM_003236 Transforming growth factor, alpha TGFA 0.169 0.082 0.080 0.028
Hs.241570 NM_000594 Tumor necrosis factor (TNF superfamily, member 2) TNG 0.076 0.044 0.097 0.026
Hs.73793 NM_003376 Vascular endothelial growth factor VEGF 0.203 0.100 0.199 0.092
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target [47]. Our results showed PDGF-A was up-
regulated during the re-initiated IFN-α treatment, indi-
cating that the residual HCC cells after the first IFN-α
treatment would likely produce alternative pro-
angiogenesis stimulator PDGF-A. Thus, angiogenesis
may rely more on the PDGF pathway than on the VEGF
pathway (Additional file 1: Figure S2).
Our findings suggest that resistance to re-initiated IFN-α
treatment results from the changing role of pro-
angiogenesis factors, which enables a transition from pri-
mary dependence on VEGF signaling to PDGF-A, at least
in the LCI-D20 model. To test this hypothesis, we com-
bined the PDGFR inhibitor imatinib with re-initiated IFN-
α treatment. Indeed, the dual blockade of pro-angiogenesis
factors produced a significant inhibition of tumor growth
by 41.5% and of angiogenesis by 40% compared with the
group treated with normal saline and by 30.7% and 31.1%
compared with re-initiated IFN-α treatment alone. We also
showed that the combination of re-initiated IFN-α treat-
ment and imatinib significantly reduced phosphorylation
of PDGFR, AKT, and ERK. These results suggest that
PDGF-A plays a role in the failure of re-initiated IFN-α
treatment. Therefore, evasion of primary anti-angiogenesis
therapy differs from tumor resistance to cytotoxic chemo-
therapy and can be treated by adding another agent. To
our knowledge, this is the first report that shows evasion of
the anti-angiogenesis effect by IFN-α treatment in HCC.
The results indicate the need for further research of a more
Figure 4 The comparison of AKT phosphorylation status among different IFN-α treatment groups. (A) Representative image showing
Western blot analysis on HCC tissues in different treatment groups using indicated antibodies. (B) Quantification of VEGF, PDGF-A, phosphor-
Y951-VEGF receptor-2, and phosphor-AKT in IFN-α treatment tumors compared with controls are shown as mean band intensity with standard
deviation, *P < 0.05.
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complicated multistage anti-angiogenesis treatment, which
would be beneficial in clinical settings.
Conclusion
In conclusion, this study demonstrated that under pressure
of IFN-α treatment, tumor angiogenesis in LCI-D20 HCC
may shift from being VEGF/VEGFR dependent to being
PDGF-A/PDGFR dependent. Up-regulation of PDGF-A is
responsible for the failure of re-initiated IFN-α treatment in
HCC because the VEGF/VEGFR signal pathway remains
inhibited. Long-term disease control can be best achieved
by combination therapy with IFN-α and PDGF-A inhibitor
in the re-initiated IFN-α treatment. This regimen merits
further investigation in clinical studies.
Additional file
Additional file 1: Additional results including 2 figures and 2
tables. Two figures (Figure S1-S2) and two tables (Table S1-S2) were
included in this file.
Figure 5 Combination of immatinib with IFN-α improved the effect of the re-initiated treatment. The combination treatment of imatinib
(100 mg/kg/day) and re-initiated IFN-α (1.5 ×10 7 U/kg/day) resulted in decreased phosphorylation of PDGFR, AKT, and ERK compared with IFN
treatment alone or control group (A), and decreased tumor weight and MVD (B); Double staining of CD31 (for endothelial cells, green) and α-
SMA (for pericyte, red) showed fewer pericytes were found in tumor vessels in combination treatment group compared with IFN-α or normal
saline treatment groups (C), scale bar = 20 μm.
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